SecBot SecBot
SECBOTREPLAY Home › Report › PCVX

PCVX · Vaxcyte reported its 2025 financial results, showing increased R&D and…

Vaxcyte, Inc. · 8-K filed Feb 24, 2026 at 16:14 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Feb 24, 2026 at 16:14 ET

Vaxcyte reported its 2025 financial results, showing increased R&D and operating expenses leading to a larger net loss, while maintaining a strong cash position of $2.44 billion. The company highlighted clinical progress on its VAX-31 vaccine program, including initiation of three Phase 3 trials and completion of enrollment in an infant Phase 2 study, along with a recent $632.5 million equity offering that strengthens its balance sheet.

  • Cash, cash equivalents and investments were $2.44 billion as of December 31, 2025, down from $3.13 billion in 2024
  • Completed $632.5 million equity offering in February 2026
  • Net loss was $766.6 million for 2025, compared to $463.9 million in 2024
  • Research and development expenses were $794.3 million for 2025, up from $476.6 million in 2024

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access